What is HC Wainwright’s Estimate for DNLI FY2028 Earnings?

Denali Therapeutics Inc. (NASDAQ:DNLI) – Research analysts at HC Wainwright lifted their FY2028 earnings estimates for shares of Denali Therapeutics in a research note issued to investors on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings per share of $4.16 for the year, up from their prior forecast of $3.98. HC Wainwright has a “Buy” rating and a $87.00 price target on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ FY2029 earnings at $6.29 EPS.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the previous year, the firm posted ($0.72) earnings per share.

DNLI has been the subject of several other reports. Baird R W upgraded Denali Therapeutics to a “strong-buy” rating in a report on Tuesday. Jefferies Financial Group boosted their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, November 1st. William Blair began coverage on shares of Denali Therapeutics in a research report on Friday, January 3rd. They issued an “outperform” rating for the company. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a report on Monday, December 16th. Finally, Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.91.

Denali Therapeutics Stock Up 6.9 %

Shares of NASDAQ DNLI opened at $21.18 on Wednesday. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.33. The firm has a market cap of $3.05 billion, a PE ratio of -7.67 and a beta of 1.39. The business has a fifty day simple moving average of $24.34 and a two-hundred day simple moving average of $24.88.

Institutional Trading of Denali Therapeutics

Large investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. lifted its holdings in shares of Denali Therapeutics by 163.7% during the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock worth $1,162,000 after purchasing an additional 24,767 shares during the period. FMR LLC raised its position in Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after buying an additional 7,596,508 shares during the last quarter. Algert Global LLC lifted its stake in Denali Therapeutics by 82.4% during the 3rd quarter. Algert Global LLC now owns 48,630 shares of the company’s stock valued at $1,417,000 after acquiring an additional 21,975 shares during the period. Integral Health Asset Management LLC purchased a new stake in shares of Denali Therapeutics in the 2nd quarter valued at $7,546,000. Finally, Principal Financial Group Inc. increased its stake in shares of Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after acquiring an additional 149,939 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Insider Activity at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 40,000 shares of Denali Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now directly owns 235,807 shares in the company, valued at approximately $6,529,495.83. The trade was a 14.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the transaction, the director now directly owns 107,976 shares in the company, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,658 shares of company stock valued at $1,667,943 in the last ninety days. Corporate insiders own 7.90% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.